INOVIQ (ASX:IIQ) Announces Blood Test for Parkinson’s Disease, Building on Alzheimer’s Success

August 20, 2024 11:27 AM AEST | By Team Kalkine Media

Google News:

INOVIQ (ASX:IIQ) Announces Blood Test for Parkinson’s Disease, Building on Alzheimer’s Success — Image source: shutterstock

Recent News

13th World Peace Forum held in Beijing, calls for shared responsibilit...

Enhancing Capacity and Logistics Flow, Minister Al-Jasser Lays Foundat...

Dalai Lama’s 90th: A Global Celebration of Compassion, Peace, and Wisd...

FAIR PLAY MENARINI INTERNATIONAL AWARD, A WAVE OF EMOTIONS MARKS THE 2...

INOVIQ (ASX:IIQ) saw its shares rise by 6% on Tuesday following the company’s announcement of a breakthrough in blood testing for Parkinson’s Disease (PD). This new development comes on the heels of a similar success with Alzheimer’s Disease (AD) reported in June.

The innovation centers around INOVIQ's proprietary software platform, NEURO-NET, which generates a computerized "protein fingerprint" from blood samples. This technology can differentiate between normal healthy blood and blood from individuals with specific neurodegenerative conditions.

NEURO-NET has shown it can identify biomarkers for both Alzheimer’s and Parkinson’s diseases, potentially allowing for earlier diagnosis and intervention. INOVIQ claims that NEURO-NET enhances the detection of known protein biomarkers by 5-8 times compared to traditional methods.

Leearne Hinch, INOVIQ’s Chief Executive and Product Officer, explained that NEURO-NET has been validated to capture brain-derived exosomes and identify blood-based exosomal protein biomarkers in both AD and PD. This capability opens up possibilities for developing blood tests for earlier detection and treatment of these diseases.

INOVIQ is now seeking partnerships with academic institutions to further validate and refine the technology, aiming to advance towards commercializing the product in the future.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.